UB Paderborn / Katalog / Suche / in CDI

US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-09, Vol.21 (5), p.559-567

2015

Volltextzugriff (PDF)

Bone health in persons with haemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-09, Vol.21 (5), p.568-577

2015

Volltextzugriff (PDF)

Physician trust and depression influence adherence to factor replacement: a single‐centre cross‐sectional study

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-01, Vol.23 (1), p.98-104

2017

Volltextzugriff (PDF)

Physical activity and functional abilities in adult males with haemophilia: a cross-sectional survey from a single US haemophilia treatment centre

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-07, Vol.19 (4), p.551-557

2013

Volltextzugriff (PDF)

Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates

Journal of thrombosis and haemostasis, 2006-12, Vol.4 (12), p.2576-2581

2006

Volltextzugriff (PDF)

Effect of late prophylaxis in hemophilia on joint status: a randomized trial

Journal of thrombosis and haemostasis, 2017-11, Vol.15 (11), p.2115-2124

2017

Volltextzugriff (PDF)

Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

Journal of thrombosis and haemostasis, 2013-06, Vol.11 (6), p.1119-1127

2013

Volltextzugriff (PDF)

Self‐reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P‐FiQ) study

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-07, Vol.23 (4), p.556-565

2017

Volltextzugriff (PDF)

Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?

Journal of thrombosis and haemostasis, 2005-08, Vol.3 (8), p.1676-1681

2005

Volltextzugriff (PDF)

Impact of pain and functional impairment in US adults with haemophilia: Patient‐reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P‐FiQ) study

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-03, Vol.24 (2), p.261-270

2018

Volltextzugriff (PDF)

Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network

Journal of thrombosis and haemostasis, 2015-09, Vol.13 (9), p.1585-1589

2015

Volltextzugriff (PDF)

Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study

Journal of thrombosis and haemostasis, 2015-11, Vol.13 (11), p.1980-1988

2015

Volltextzugriff (PDF)

Distributed optimisation and control of graph Laplacian eigenvalues for robust consensus via an adaptive multilayer strategy

International journal of robust and nonlinear control, 2017-06, Vol.27 (9), p.1499-1525

2017

Volltextzugriff (PDF)

Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-01, Vol.20 (1), p.25-31

2014

Volltextzugriff (PDF)

Survey of the anti–factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence‐based immunoassay

Journal of thrombosis and haemostasis, 2016-10, Vol.14 (10), p.1931-1940

2016

Volltextzugriff (PDF)

Bone density in haemophilia: a single institutional cross-sectional study

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-01, Vol.20 (1), p.121-128

2014

Volltextzugriff (PDF)

A cross‐sectional study of non‐attendance among patients at a US hemophilia treatment center 2010‐2014

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-11, Vol.24 (6), p.902-910

2018

Volltextzugriff (PDF)

Inhibitors in previously treated patients: a review of the literature

Haemophilia : the official journal of the World Federation of Hemophilia, 2010-05, Vol.16 (102), p.61-65

KEMPTON, C. L.

2010

Volltextzugriff (PDF)

Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-09, Vol.18 (5), p.798-804

2012

Volltextzugriff (PDF)

In non‐severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case–control study

Journal of thrombosis and haemostasis, 2010-10, Vol.8 (10), p.2224-2231

2010

Volltextzugriff (PDF)

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-01, Vol.24 (1), p.104-112

2018

Volltextzugriff (PDF)

The role of disease severity in influencing body mass index in people with haemophilia: a single-institutional cross-sectional study

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-03, Vol.20 (2), p.190-195

2014

Volltextzugriff (PDF)

A study of prospective surveillance for inhibitors among persons with haemophilia in the United States

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-03, Vol.20 (2), p.230-237

2014

Volltextzugriff (PDF)

Mitral valve repair in a Jehovah's witness with haemophilia A with high-titre inhibitor

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-11, Vol.21 (6), p.e523-e525

2015

Volltextzugriff (PDF)

Distress in patients with bleeding disorders: a single institutional cross-sectional study

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-11, Vol.21 (6), p.e456-e464

2015

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors

Bone health in persons with haemophilia

Physician trust and depression influence adherence to factor replacement: a single‐centre cross‐sectional study

Physical activity and functional abilities in adult males with haemophilia: a cross-sectional survey from a single US haemophilia treatment centre

Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates

Effect of late prophylaxis in hemophilia on joint status: a randomized trial

Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

Self‐reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P‐FiQ) study

Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?

Impact of pain and functional impairment in US adults with haemophilia: Patient‐reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P‐FiQ) study

Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network

Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study

Distributed optimisation and control of graph Laplacian eigenvalues for robust consensus via an adaptive multilayer strategy

Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database

Survey of the anti–factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence‐based immunoassay

Bone density in haemophilia: a single institutional cross-sectional study

A cross‐sectional study of non‐attendance among patients at a US hemophilia treatment center 2010‐2014

Inhibitors in previously treated patients: a review of the literature

Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A

In non‐severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case–control study

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients

The role of disease severity in influencing body mass index in people with haemophilia: a single-institutional cross-sectional study

A study of prospective surveillance for inhibitors among persons with haemophilia in the United States

Mitral valve repair in a Jehovah's witness with haemophilia A with high-titre inhibitor

Distress in patients with bleeding disorders: a single institutional cross-sectional study

Suchergebnisse filtern